TALK Earnings

TALK reported its FY2025Q4 earnings on 2026-02-23, showcasing a revenue of 0.00 against an estimate of 63.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.02 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following TALK's FY2025Q4 earnings announcement on 2026-02-23, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, TALK's stock price tends to shift by an average of +0.72% in the 10 days leading up to earnings and +2.84% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate TALK’s annual revenue to reach 62.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 1.54% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between TALK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 1.54% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TALK's stock price typically moves by +0.72% in the 10 days before its earnings and +2.84% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 62.00M.

The earnings call reveals strong growth drivers, including a 30%+ annual growth in the payer business, strategic AI investments, and operational efficiencies. The Q&A highlights positive sentiment towards AI integration and marketing efficiency, with analysts showing interest in new partnerships and acquisitions. While guidance remains unchanged, the company's strategic initiatives and a $17.2 million share repurchase indicate confidence. Despite some uncertainties, like Medicare impact, the overall sentiment is positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks.